Marketing-authorisation holder · Canada
Novo Nordisk Canada Inc
128 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Canada
128 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 128
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ACTIVELLE1 mg + 0.5 mg · Tablet | Estradiol, Norethindrone | Canada | Marketed | 2008 |
| ACTIVELLE LD0.5 mg + 0.1 mg · Tablet | Estradiol, Norethindrone | Canada | Marketed | 2008 |
| ALHEMO60 mg / 1.5 ml · Solution | Concizumab | Canada | Authorised | |
| ALHEMO300 mg / 3 ml · Solution | Concizumab | Canada | Authorised | |
| ALHEMO15 mg / 1.5 ml · Solution | Concizumab | Canada | Authorised | |
| ALHEMO150 mg / 1.5 ml · Solution | Concizumab | Canada | Authorised | |
| AWIQLI700 unit / ml · Solution | Insulin icodec | Canada | Marketed | 2024 |
| AWIQLI2100 unit / 3 ml · Solution | Insulin icodec | Canada | Marketed | 2024 |
| AWIQLI1050 unit / 1.5 ml · Solution | Insulin icodec | Canada | Marketed | 2024 |
| ESPEROCT2000 unit / vial · Powder For Solution | Antihemophilic factor | Canada | Marketed | 2022 |
| ESPEROCT500 unit / vial · Powder For Solution | Antihemophilic factor | Canada | Marketed | 2022 |
| ESPEROCT1500 unit / vial · Powder For Solution | Antihemophilic factor | Canada | Authorised | |
| ESPEROCT3000 unit / vial · Powder For Solution | Antihemophilic factor | Canada | Marketed | 2022 |
| ESPEROCT1000 unit / vial · Powder For Solution | Antihemophilic factor | Canada | Marketed | 2022 |
| FIASP100 unit / ml · Solution | Insulin aspart | Canada | Marketed | 2017 |
| FIASP100 unit / ml · Solution | Insulin aspart | Canada | Marketed | 2017 |
| FIASP100 unit / ml · Solution | Insulin aspart | Canada | Not marketed | 2017 |
| FREHEMGO1.6 mg / 0.8 ml · Solution | Denecimig | Canada | Authorised | |
| FREHEMGO46 mg / 0.8 ml · Solution | Denecimig | Canada | Authorised | |
| FREHEMGO9 mg / 0.8 ml · Solution | Denecimig | Canada | Authorised | |
| FREHEMGO4 mg / 0.8 ml · Solution | Denecimig | Canada | Authorised | |
| FREHEMGO20 mg / 0.8 ml · Solution | Denecimig | Canada | Authorised | |
| LEVEMIR PENFILL100 unit / ml · Solution | Insulin detemir | Canada | Not marketed | 2005 |
| NIASTASE RT8 mg / vial · Kit, Powder For Solution | Coagulation factor viia | Canada | Authorised | |
| NIASTASE RT2 mg / vial · Kit, Powder For Solution | Coagulation factor viia | Canada | Marketed | 2015 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 128 | 100 | 28 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.